5 Stocks Driving The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 23 points (-0.2%) at 15,060 as of Friday, May 10, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,550 issues advancing vs. 1,371 declining with 121 unchanged.

The Health Services industry currently sits up 0.6% versus the S&P 500, which is unchanged. Top gainers within the industry include Unilife Corporation ( UNIS), up 58.4%, St Jude Medical ( STJ), up 1.9%, Edwards Life ( EW), up 1.5%, Boston Scientific ( BSX), up 1.4% and HCA Holdings ( HCA), up 1.5%. On the negative front, top decliners within the industry include Grifols ( GRFS), down 3.28, and Intuitive Surgical ( ISRG), down 2.41.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Hologic ( HOLX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Hologic is up $0.66 (3.19) to $21.16 on average volume Thus far, 1.8 million shares of Hologic exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $20.58-$21.24 after having opened the day at $20.60 as compared to the previous trading day's close of $20.51.

Hologic, Inc. develops, manufactures, and supplies diagnostics, medical imaging systems, and surgical products for the healthcare needs of women. Hologic has a market cap of $5.4 billion and is part of the health care sector. Shares are up 1.6% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Hologic a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Hologic as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Hologic Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Hologic Looks Good on the Charts

Five S&P 500 Boards Have No Women as Gender Balance Growth Stalls

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Cramer: These Sectors Look Bullish (Part III)